Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Toni K. Choueiri, M.D.

Co-Author

This page shows the publications co-authored by Toni Choueiri and David McDermott.
Connection Strength

9.102
  1. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Invest New Drugs. 2021 08; 39(4):1019-1027.
    View in: PubMed
    Score: 0.951
  2. Author Correction: Inhibition of hypoxia-inducible factor-2a in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021 Oct; 27(10):1849.
    View in: PubMed
    Score: 0.249
  3. Inhibition of hypoxia-inducible factor-2a in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021 05; 27(5):802-805.
    View in: PubMed
    Score: 0.242
  4. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Eur Urol. 2021 05; 79(5):665-673.
    View in: PubMed
    Score: 0.239
  5. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.238
  6. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. Eur J Cancer. 2021 03; 145:1-10.
    View in: PubMed
    Score: 0.237
  7. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol. 2020 12 20; 38(36):4240-4248.
    View in: PubMed
    Score: 0.234
  8. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol. 2020 10 01; 6(10):1606-1610.
    View in: PubMed
    Score: 0.233
  9. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
    View in: PubMed
    Score: 0.227
  10. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
    View in: PubMed
    Score: 0.219
  11. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Dec; 24(12):1941.
    View in: PubMed
    Score: 0.205
  12. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2019 02; 24(2):202-210.
    View in: PubMed
    Score: 0.201
  13. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 06; 24(6):749-757.
    View in: PubMed
    Score: 0.198
  14. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018 04; 19(4):451-460.
    View in: PubMed
    Score: 0.195
  15. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018 03; 19(3):405-415.
    View in: PubMed
    Score: 0.194
  16. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunol Res. 2018 04; 6(4):402-408.
    View in: PubMed
    Score: 0.193
  17. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol. 2016 Oct 20; 34(30):3655-3663.
    View in: PubMed
    Score: 0.177
  18. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 07; 14(7):820-4.
    View in: PubMed
    Score: 0.173
  19. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul; 17(7):917-927.
    View in: PubMed
    Score: 0.172
  20. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
    View in: PubMed
    Score: 0.172
  21. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471.
    View in: PubMed
    Score: 0.171
  22. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2016 Dec 15; 2(6):633-639.
    View in: PubMed
    Score: 0.171
  23. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):304-313.e6.
    View in: PubMed
    Score: 0.169
  24. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.166
  25. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. Eur J Cancer. 2015 Nov; 51(17):2580-6.
    View in: PubMed
    Score: 0.164
  26. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 01; 121(19):3435-43.
    View in: PubMed
    Score: 0.161
  27. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol. 2015 Jun 20; 33(18):2013-20.
    View in: PubMed
    Score: 0.159
  28. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol. 2014 Apr; 65(4):723-30.
    View in: PubMed
    Score: 0.144
  29. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
    Score: 0.135
  30. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013 Jan 10; 31(2):181-6.
    View in: PubMed
    Score: 0.135
  31. Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol. 2012 Feb 10; 30(5_suppl):364.
    View in: PubMed
    Score: 0.128
  32. A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. J Clin Oncol. 2012 Feb 10; 30(5_suppl):355.
    View in: PubMed
    Score: 0.128
  33. The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer. 2012 Jan 15; 118(2):365-70.
    View in: PubMed
    Score: 0.122
  34. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011 May; 59(5):856-62.
    View in: PubMed
    Score: 0.119
  35. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25.
    View in: PubMed
    Score: 0.117
  36. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011 Jan; 185(1):60-6.
    View in: PubMed
    Score: 0.117
  37. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. Urol Oncol. 2012 Nov-Dec; 30(6):848-55.
    View in: PubMed
    Score: 0.116
  38. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. 2011 Nov-Dec; 29(6):756-63.
    View in: PubMed
    Score: 0.113
  39. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Sep; 106(6):772-8.
    View in: PubMed
    Score: 0.112
  40. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2010 May; 105(9):1247-54.
    View in: PubMed
    Score: 0.109
  41. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 01; 27(34):5794-9.
    View in: PubMed
    Score: 0.109
  42. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 May 10; 39(5):632-648.e8.
    View in: PubMed
    Score: 0.060
  43. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380.
    View in: PubMed
    Score: 0.059
  44. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020 11; 5(6):e001079.
    View in: PubMed
    Score: 0.058
  45. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.058
  46. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2021 01 01; 27(1):78-86.
    View in: PubMed
    Score: 0.058
  47. Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clin Cancer Res. 2020 11 01; 26(21):5598-5608.
    View in: PubMed
    Score: 0.058
  48. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020 09 15; 126(18):4156-4167.
    View in: PubMed
    Score: 0.057
  49. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 07; 8(2).
    View in: PubMed
    Score: 0.057
  50. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int. 2020 07; 126(1):73-82.
    View in: PubMed
    Score: 0.056
  51. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019 09 25; 10(1):4346.
    View in: PubMed
    Score: 0.054
  52. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 10; 20(10):1370-1385.
    View in: PubMed
    Score: 0.054
  53. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 06 15; 393(10189):2404-2415.
    View in: PubMed
    Score: 0.053
  54. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
    View in: PubMed
    Score: 0.052
  55. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
    View in: PubMed
    Score: 0.052
  56. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018 09; 14(9):e1007679.
    View in: PubMed
    Score: 0.051
  57. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):341-348.
    View in: PubMed
    Score: 0.049
  58. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 05; 378(14):1277-1290.
    View in: PubMed
    Score: 0.049
  59. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815.
    View in: PubMed
    Score: 0.048
  60. Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 2017 Nov 28; 8(61):103428-103436.
    View in: PubMed
    Score: 0.047
  61. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Eur Urol. 2017 09; 72(3):368-376.
    View in: PubMed
    Score: 0.046
  62. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
    View in: PubMed
    Score: 0.042
  63. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 05; 373(19):1803-13.
    View in: PubMed
    Score: 0.041
  64. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64.
    View in: PubMed
    Score: 0.040
  65. Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). J Clin Oncol. 2012 Feb 10; 30(5_suppl):372.
    View in: PubMed
    Score: 0.032
  66. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int. 2011 Oct; 108(8):1279-83.
    View in: PubMed
    Score: 0.030
  67. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010 Aug; 76(2):430-4.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.